Key clinical point: Both first- and second-line s ecukinumab therapies demonstrated substantial improvement in disease activity , adequate retention rates, and a satisfactory safety profile in a real-world population of patients with psoriatic arthritis (PsA).
Major finding: Mean Disease Activity Score 28 using C-reactive protein decreased from 3.0 to 2.0 and 1.9 at the first and third years of follow-up, whereas the proportion of patients in remission/low disease activity increased from 52.1% and 71.4% to 100% after 2 years of the first- and second-line secukinumab treatments, respectively. The overall retention rates of secukinumab were 74.1%, 59.1%, and 54.2% in the first, second, and third years of treatment, respectively, with no new adverse events being reported.
Study details: This observational, retrospective analysis included 639 patients with PsA or axial spondyloarthritis from the BIOBADASER registry who had received secukinumab for >12 months. Of these patients, 350 had PsA.
Disclosures: This study was sponsored by Novartis Spain. C Sastr é is an employee of Novartis. The other authors reported no conflicts of interest.
Source: Moreno-Ramos MJ et al. Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: A descriptive observational analysis of the Spanish BIOBADASER Registry. Rheumatol Ther. 2022 (Apr 25). Doi: 10.1007/s40744-022-00446-9